Patients who are seemingly well controlled with diet, exercise, and medical therapy, even those with normal FPG and HbA1c could have uncontrolled PPHG. The combination of improved detection and monitoring of PPHG along with effective medications may help to establish optimal glycemic control thereby reducing diabetic complications.
A special care in the identification of UC-RHTN patients (including its extreme phenotype, RfHTN) might lead to a better understanding and treatment of this harder-to-control RHTN subgroup.
The complex network of reciprocal interconnections between the heart and the main biological systems provides a new vision of cardiovascular science based on psychoneuroendocrineimmunology.
The increased activity of G6PD in type 2 diabetics is associated with dyslipidemia resulting in failure of lipid homeostasis
As survival for children born with CHDs have increased over the past decades, these data underscore the importance of establishing more specialized ACHD care facilities in order to meet the health care needs of this growing population.
The United States Food and Drug Administration (FDA) has published new proposed guidance to the industry on assessing the safety of type 2 diabetes newer medications and withdrawn the 12-year “outdated” conditions for standardized cardiovascular outcome trials (CVOT).
